felbamate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tranquillizers, propanediol and pentanediol derivatives 1140 25451-15-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • felbamate
  • felbamyl
  • felbatol
A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.
  • Molecular weight: 238.24
  • Formula: C11H14N2O4
  • CLOGP: 0.50
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 104.64
  • ALOGS: -2.51
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.74 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 45 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 251.84 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,STK33,TEK,TTK 31
kinase-selectivity-class AXL,CAMK2D,FLT3,GRK2,JAK2,MAP2K6,MAPK7,PDK4,SIK2,STK33,TEK 11
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1

Approvals:

DateAgencyCompanyOrphan
July 29, 1993 FDA MEDA PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 197.73 58.17 70 892 152559 90474926
Electrocardiogram ST segment elevation 79.02 58.17 16 946 4000 90623485
Laryngeal stenosis 75.74 58.17 13 949 1326 90626159
Unmasking of previously unidentified disease 74.48 58.17 13 949 1463 90626022
Electrocardiogram repolarisation abnormality 68.62 58.17 12 950 1364 90626121
Multiple-drug resistance 68.49 58.17 16 946 7760 90619725
Systolic dysfunction 64.73 58.17 12 950 1892 90625593
Tachycardia 64.58 58.17 32 930 157641 90469844
Electrocardiogram QRS complex prolonged 64.08 58.17 15 947 7333 90620152
Cardiotoxicity 62.42 58.17 16 946 11373 90616112
Drug reaction with eosinophilia and systemic symptoms 60.20 58.17 21 941 42737 90584748

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 308.59 49.40 112 892 120449 42499882
Drug ineffective 88.09 49.40 89 915 630108 41990223
Generalised tonic-clonic seizure 87.37 49.40 30 974 26349 42593982
Benzodiazepine drug level decreased 55.08 49.40 7 997 35 42620296

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 356.28 46.74 132 1608 221053 110366506
Multiple-drug resistance 99.91 46.74 26 1714 13209 110574350
Generalised tonic-clonic seizure 95.90 46.74 35 1705 54645 110532914
Drug ineffective 95.21 46.74 117 1623 1520423 109067136
Laryngeal stenosis 70.04 46.74 13 1727 1385 110586174
Unmasking of previously unidentified disease 60.72 46.74 13 1727 2855 110584704
Electrocardiogram ST segment elevation 59.57 46.74 16 1724 9144 110578415
Benzodiazepine drug level decreased 57.89 46.74 7 1733 35 110587524
Petit mal epilepsy 57.77 46.74 15 1725 7532 110580027
Electrocardiogram repolarisation abnormality 57.54 46.74 12 1728 2323 110585236
Somnolence 57.48 46.74 43 1697 297406 110290153
Toxicity to various agents 54.46 46.74 51 1689 480504 110107055
Systolic dysfunction 49.93 46.74 12 1728 4403 110583156
Cardiotoxicity 49.91 46.74 16 1724 16865 110570694
Electrocardiogram QRS complex prolonged 49.67 46.74 15 1725 13006 110574553

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AX10 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Other antiepileptics
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
MeSH PA D000927 Anticonvulsants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018691 Excitatory Amino Acid Antagonists
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:63726 neuroprotective agent
CHEBI has role CHEBI:75835 anti-anaemic agent
FDA EPC N0000175753 Anti-epileptic Agent

Related Drugs by ATC class:

N03AX Other antiepileptics 18 drugs
beclamidebrivaracetamcannabidiolcarisbamatecenobamatefenfluramineganaxolonelacosamidelamotriginelevetiracetamperampanelphenacemide show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Epilepsy indication 84757009 DOID:1826
Lennox-Gastaut syndrome indication 230418006
Simple partial seizure indication 117891000119100
Suicidal thoughts contraindication 6471006
Torsades de pointes contraindication 31722008
Depressive disorder contraindication 35489007
Hepatic failure contraindication 59927004
Kidney disease contraindication 90708001 DOID:557
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Disease of liver contraindication 235856003 DOID:409
Aplastic anemia contraindication 306058006 DOID:12449
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Porphyria contraindication 418470004
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.24 acidic
pKa2 13.84 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glutamate receptor ionotropic, NMDA 2A Ion channel ANTAGONIST DRUGBANK CHEMBL
Glutamate receptor ionotropic, NMDA 2B Ion channel ANTAGONIST IC50 4.28 WOMBAT-PK CHEMBL

External reference:

IDSource
4020832 VUID
N0000148344 NUI
D00536 KEGG_DRUG
4020832 VANDF
C0060135 UMLSCUI
CHEBI:4995 CHEBI
CHEMBL1094 ChEMBL_ID
DB00949 DRUGBANK_ID
D000078328 MESH_DESCRIPTOR_UI
3331 PUBCHEM_CID
5473 IUPHAR_LIGAND_ID
5686 INN_ID
X72RBB02N8 UNII
224900 RXNORM
185493 MMSL
3074 MMSL
4715 MMSL
d03170 MMSL
004277 NDDF
371387009 SNOMEDCT_US
96194006 SNOMEDCT_US
X72RBB02N8 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Felbatol HUMAN PRESCRIPTION DRUG LABEL 1 0037-0430 TABLET 400 mg ORAL NDA 33 sections
Felbatol HUMAN PRESCRIPTION DRUG LABEL 1 0037-0431 TABLET 600 mg ORAL NDA 33 sections
Felbatol HUMAN PRESCRIPTION DRUG LABEL 1 0037-0442 SUSPENSION 600 mg ORAL NDA 33 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 10135-601 TABLET 400 mg ORAL ANDA 28 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 10135-602 TABLET 600 mg ORAL ANDA 28 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 16714-775 SUSPENSION 600 mg ORAL ANDA 33 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 51672-4172 SUSPENSION 600 mg ORAL ANDA 33 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 51672-4185 TABLET 400 mg ORAL ANDA 33 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 51672-4186 TABLET 600 mg ORAL ANDA 33 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 53746-734 TABLET 400 mg ORAL ANDA 15 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 53746-735 TABLET 600 mg ORAL ANDA 15 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 62559-730 TABLET 400 mg ORAL ANDA 31 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 62559-730 TABLET 400 mg ORAL ANDA 31 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 62559-731 TABLET 600 mg ORAL ANDA 31 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 62559-731 TABLET 600 mg ORAL ANDA 31 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 63629-1937 TABLET 400 mg ORAL ANDA 31 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 63629-1944 TABLET 600 mg ORAL ANDA 31 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 65162-686 SUSPENSION 600 mg ORAL ANDA 16 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 65162-734 TABLET 400 mg ORAL ANDA 15 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 65162-735 TABLET 600 mg ORAL ANDA 15 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 68151-4474 TABLET 600 mg ORAL ANDA 15 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 70771-1077 TABLET 400 mg ORAL ANDA 2 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 70771-1078 TABLET 600 mg ORAL ANDA 2 sections
Felbamate Human Prescription Drug Label 1 70954-051 SUSPENSION 600 mg ORAL ANDA 16 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 72162-1770 TABLET 400 mg ORAL ANDA 31 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 72162-1771 TABLET 600 mg ORAL ANDA 31 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 72578-056 TABLET 400 mg ORAL ANDA 27 sections
Felbamate HUMAN PRESCRIPTION DRUG LABEL 1 72578-057 TABLET 600 mg ORAL ANDA 27 sections